Clinical Trial
Does 1,25(OH)2D3 accelerate spinal bone loss? A controlled therapeutic trial in 70-year-old women
- PMID: 3881203
Item in Clipboard
Clinical Trial
Does 1,25(OH)2D3 accelerate spinal bone loss? A controlled therapeutic trial in 70-year-old women
Clin Orthop Relat Res.
1985 Jan-Feb.
Abstract
The progress of spinal bone loss was monitored by measurements of the vertebral body height of T6 to L5 in seventy 70-year-old women who participated in a controlled, double-blind therapeutic trial. They were treated for one year by 1,25(OH)2D3, 0.50 micrograms a day (or less if hypercalcemia occurred) and cyclical estrogen/gestagen, alone or combined, or placebo. Sufficient calcium intake was ensured in all. The vertebral body height decreased significantly, by 1%, in both of the 1,25(OH)2D3 groups, whereas it remained unchanged in the hormone and the placebo + calcium group. This observation does not encourage the use of 1,25(OH)2D3 for prevention or treatment of postmenopausal bone loss.
Similar articles
-
Treatment of post menopausal osteoporosis. A controlled therapeutic trial comparing oestrogen/gestagen, 1,25-dihydroxy-vitamin D3 and calcium.Clin Endocrinol (Oxf). 1982 May;16(5):515-24. doi: 10.1111/j.1365-2265.1982.tb02769.x. Clin Endocrinol (Oxf). 1982. PMID: 7044620 Clinical Trial.
-
Effect of 1,25-dihydroxy-vitamin D3 in itself or combined with hormone treatment in preventing postmenopausal osteoporosis.Eur J Clin Invest. 1981 Aug;11(4):305-9. doi: 10.1111/j.1365-2362.1981.tb02121.x. Eur J Clin Invest. 1981. PMID: 6795047 Clinical Trial.
-
Clinical, biochemical and histological results of a double-blind trial with 1,25-dihydroxyvitamin D3, estradiol and placebo in post-menopausal osteoporosis.Acta Vitaminol Enzymol. 1984;6(2):117-28. Acta Vitaminol Enzymol. 1984. PMID: 6388277 Clinical Trial.
-
Use of low-dosage 17 beta-estradiol for the prevention of osteoporosis.Clin Ther. 1993 Nov-Dec;15(6):950-62; discussion 949. Clin Ther. 1993. PMID: 8111815 Review.
-
1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.Dan Med Bull. 2008 Nov;55(4):186-210. Dan Med Bull. 2008. PMID: 19232159 Review.
Cited by
-
Environmental and Genetic Determinants of Serum 25(OH)-Vitamin D Levels during Pregnancy and Early Childhood.Children (Basel). 2019 Oct 21;6(10):116. doi: 10.3390/children6100116. Children (Basel). 2019. PMID: 31640192 Free PMC article.
-
Vitamin D supplementation for prevention of mortality in adults.Cochrane Database Syst Rev. 2014 Jan 10;2014(1):CD007470. doi: 10.1002/14651858.CD007470.pub3. Cochrane Database Syst Rev. 2014. PMID: 24414552 Free PMC article.
-
Combined treatment with calcitonin and 1,25-dihydroxyvitamin D3 for osteoporosis in women.Calcif Tissue Int. 1993 Jul;53(1):26-8. doi: 10.1007/BF01352011. Calcif Tissue Int. 1993. PMID: 8348381
-
Effects of 1 alpha-hydroxyvitamin D3 on lumbar bone mineral density and vertebral fractures in patients with postmenopausal osteoporosis.Calcif Tissue Int. 1994 May;54(5):370-6. doi: 10.1007/BF00305521. Calcif Tissue Int. 1994. PMID: 8062152 Clinical Trial.
-
Vitamin D and vitamin D analogues for preventing fractures in post-menopausal women and older men.Cochrane Database Syst Rev. 2014 Apr 14;2014(4):CD000227. doi: 10.1002/14651858.CD000227.pub4. Cochrane Database Syst Rev. 2014. PMID: 24729336 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical